Related Experiment Video
Updated: May 13, 2026
07:36
Isolation of Human Lymphatic Endothelial Cells by Multi-parameter Fluorescence-activated Cell Sorting
Published on: May 1, 2015
14.4K
Lymphatic Interventions in Congenital Heart Disease
Surendranath Veeram Reddy1, Sanjay Prakash Sinha2
1Childrens/UT Southwestern Medical Center, Heart Center, B 405, Childrens Medical Center, 1935 Medical District Drive, Dallas, TX 75235, USA.
Interventional Cardiology Clinics
|June 5, 2024
Summary
Congenital heart disease can cause lymphatic disorders in the chest or abdomen. While selective lymphatic duct embolization is a common treatment, novel decompression strategies show promise for better long-term outcomes.
Area of Science:
- Cardiology
- Radiology
- Vascular Surgery
Background:
- Lymphatic disorders present a significant challenge in patients with congenital heart disease.
- These disorders can manifest in the chest, abdomen, or multiple compartments, impacting patient health.
Purpose of the Study:
- To review the diagnostic modalities and therapeutic interventions for lymphatic disorders associated with congenital heart disease.
- To discuss the efficacy and limitations of current treatments and explore emerging strategies.
Main Methods:
- Utilized heavily T2-weighted noninvasive lymphatic imaging for anatomical assessment.
- Employed invasive dynamic contrast magnetic resonance lymphangiography for evaluating lymphatic flow.
- Reviewed outcomes of selective lymphatic duct embolization (SLDE) and compared it to total thoracic duct embolization.
Main Results:
- Noninvasive and invasive lymphatic imaging are key diagnostic tools for identifying the cause of lymphatic disorders.
- Selective lymphatic duct embolization (SLDE) is now the preferred therapeutic procedure over total thoracic duct embolization.
- A notable recurrence rate necessitates repeat interventions in patients treated with SLDE.
Conclusions:
- While SLDE is a primary intervention, its recurrence rate highlights the need for improved therapeutic approaches.
- Emerging surgical and transcatheter thoracic duct decompression strategies offer potential for better long-term management.
- Long-term follow-up data is crucial for validating the effectiveness of these novel interventions.
Related Concept Videos
01:16Lymphatic Vessels and Lymph Transport
Lymphatic vessels, known as lymphatics, are crucial in transporting lymph from peripheral tissues to our venous system. This process begins with lymph entering through tiny capillaries that branch through tissues. These capillaries have unique features such as larger diameters, thinner walls, and a distinctive one-way valve system formed by overlapping endothelial cells.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular spaces.
This one-way system allows fluids, solutes, and even pathogens to enter but prevents their return to the intercellular spaces.
01:15Development of the Lymphatic System
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...